

**Thomas F. Schulz, Dr. med., D.o.B. 08-10-1953**

Senior Professor of Virology, Institute of Virology, Medizinische Hochschule Hannover

**Undergraduate and Postgraduate Training**

1972–1979	Medical School in Mainz, Montpellier and London
1980	Medical Doctorate (Dr. med.; Supervisor Prof. Dr. med. M.P. Dierich)
1986	Habilitation (Supervisor Prof. Dr. med. M.P. Dierich)
1990	Certificate of Completed Specialist Training in Medical Microbiology, Virology, Infection Epidemiology
1998	Member of the Royal College of Pathologists (MRCPATH)
2003	Fellow of the Royal College of Pathologists (FRCPath)

**Academic and Research Posts**

1979-1981	Assistant Physician I. Med. Klinik, Div. Haematology, Mainz University
1981-1983	Postgraduate Trainee, Institute of Med. Microbiology, Mainz University
1983-1986	Postgraduate Assistant, Institute of Hygiene, Innsbruck University
1986-1988	University Lecturer, Institute of Hygiene, Innsbruck University
1988-1990	EMBO Fellow, Institute of Cancer Research, London
1990-1995	Clinical Research Scientist, Institute of Cancer Research, London
1995-2000	Full Professor, Dept. Medical Microbiology, The University of Liverpool
2000-2024	Full (C4) Professor of Virology and Director, Institute of Virology, MHH
2024-	Senior Professor of Virology, Institute of Virology, MHH

**Other Scientific Roles**

1997-2005	Associate Editor, <i>Journal of General Virology</i>
2005-2007	Member of the DFG Senat Committee for Collaborative Research Centers (Sonderforschungsbereiche)
2006-2010	Coordinator, EU Integrated Program INCA (LSHC-CT-2005- 018704)
2010-2022	Speaker, DFG Collaborative Research Centre 900 "Chronic Infections: Microbial Persistence and its control"
2009	Chair of the IARC/WHO ('International Agency for Research against Cancer') expert panel to evaluate the cancerogenic risk of biological agents to humans
2010-2015	Chair, Scientific Advisory Board of the German Primate Centre, Göttingen
2010-2016	Chair, Scientific Advisory Board of the Heinrich-Pette-Institute of Virology, Hamburg
2016-2024	Member, Board ("Kuratorium") of the Leibniz Institute of Virology (LIV), Hamburg
2012-2019	Member, Internal Advisory Board, German Centre for Infection Research (DZIF)
2019-2024	Speaker, DFG Cluster of Excellence RESIST (EXC 2155)
2019-	Coordinator, German Center for Infection Research Area (TTU) Infections of the Immunocompromised Host
2020-	Associate Editor, <i>PLoS Pathogens</i>
2021-2025	Member, Scientific Advisory Board of the Helmholtz Institute of RNA-based Infection Research, Würzburg

**Awards and Prizes**

1972-1979	German National Scholarship Foundation (Studienstiftung des Deutschen Volkes)
1986	Longterm EMBO Fellowship
1997	Parkes-Weber Medal of the Royal College of Physicians
2014	Medal of the German Primate Centre
2025	Wissenschaftspreis der Fritz-Behrens Stiftung

**Current Funding**

DFG Cluster of Excellence RESIST (Former speaker and project leader), DZIF TTU IICH.

## Selected Publications (of > 300 publications)

1. Stein SC, Ssebyatika G, Benecke T, Ströh L, Rajak MK, Vollmer B, Menz S, Waldmann J-Y, Tipp SN, Ochulor O, Herold E, Schwarzloh B, Mutschall D, Zischke J, Schneider T, Hinrichs I, Blasczyk R, Kleine-Weber H, Hoffmann M, Klein F, Kaiser FK, Gonzalez-Hernandez M, Armando F, Ciurkiewicz M, Beythien G, Pöhlmann S, Baumgärtner W, Gruenewald K, Osterhaus A, Schulz TF, Krey T, Hansen G. A critical residue in a conserved RBD epitope determines neutralization breadth of pan-sarbecovirus antibodies with recurring YYDRxxG motifs. *mBio* 2025; 16(9): e0060625. doi: 10.1128/mbio.00606-25.
2. Stein SC, Hansen G, Ssebyatika G, Ströh LJ, Ochulor O, Herold E, Schwarzloh B, Mutschall D, Zischke J, Cordes AK, Schneider T, Hinrichs I, Blasczyk R, Kleine-Weber H, Hoffmann M, Klein F, Kaiser FK, Gonzalez-Hernandez M, Armando F, Ciurkiewicz M, Beythien G, Pöhlmann S, Baumgärtner W, Osterhaus A, Schulz TF, Krey T. A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation. *J. Virol.* 2024; 98: e0122324. doi: 10.1128/jvi.01223-24
3. Sake SM, Zhang X, Rajak MK, Urbanek-Quaing M, Carpentier A, Gunesch AP, Grethe C, Matthaei A, Rückert J, Galloux M, Larcher T, Le Goffic R, Hontonnou F, Chatterjee AK, Johnson K, Morwood K, Rox K, Elgaher WAM, Huang J, Wetzke M, Hansen G, Fischer N, Eléouët JF, Rameix-Welti MA, Hirsch AKH, Herold E, Empting M, Lauber C, Schulz TF, Krey T, Haid S, Pietschmann T. Drug Repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor. *Nat. Comm*, 2024; 15:1173. doi: 10.1038/s41467-024-45241-y
4. Berwanger A, Stein SC, Kany AM, Gartner M, Loretz B, Lehr CM, Hirsch AKH, Schulz TF, Empting M. Disrupting Kaposi's Sarcoma-associated Herpesvirus (KSHV) latent replication with a small molecule inhibitor. *J Med Chem.* 2023; 66:10782-10790. doi: 10.1021/acs.jmedchem.3c00990.
5. Schulz TF, Freise A, Stein SC. Kaposi Sarcoma-associated herpesvirus latent nuclear antigen: more than a key regulator of viral persistence. *Curr Opin Virol.* 2023; 61:101336. doi: 10.1016/j.coviro.2023.101336.
6. McLean G, Kamil J, Lee B, Moore P, Schulz TF, Muik A, Sahin U, Türeci Ö, Pather S. The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines. *mBio* 2022; 13(2):e0297921. doi: 10.1128/mbio.02979-21.
7. Naniima P, Naimo E, Koch S, Curth U, Alkharsah KR, Ströh LJ, Binz A, Benecke JM, Vollmer B, Böning H, Borst EM, Desai P, Bohne J, Messerle M, Bauerfeind R, Legrand P, Sodeik B, Schulz TF, Krey T. Assembly of infectious Kaposi's sarcoma-associated herpesvirus progeny requires formation of a pORF19 pentamer. *PLoS Biology* 2021; 19(11):e3001423. doi: 10.1371/journal.pbio.3001423.
8. Samarina N, Ssebyatika G, Tikla T, Waldmann JY, Abere B, Nanna V, Marasco M, Carlomagno T, Krey T, Schulz TF Recruitment of phospholipase C $\gamma$ 1 to the non-structural membrane protein pK15 of Kaposi Sarcoma-associated herpesvirus promotes its Src-dependent phosphorylation. *PLoS Pathogens* 2021; 17(6):e1009635. <https://doi.org/10.1371/journal.ppat.1009635>
9. Lotke R, Schneeweiß U, Pietrek M, Günther T, Grundhoff A, Weidner-Glunde M, Schulz TF Brd/BET proteins influence the genome-wide localisation of the Kaposi's Sarcoma-Associated Herpesvirus and Murine Gammaherpesvirus major latency proteins. *Frontiers in Microbiology* 2020; 11:591778. doi: 10.3389/fmicb.2020.591778
10. Beauclair G, Naimo E, Dubich T, Rückert J, Koch S, Dhingra A, Wirth D, Schulz TF Targeting Kaposi's Sarcoma-associated Herpesvirus ORF21 tyrosine kinase and viral lytic replication with tyrosine kinase inhibitors approved for clinical use. *J. Virol.* 2020; 94: e01791-19
11. Kirsch P, Stein SC, Berwanger A, Rinkes J, Jakob V, Schulz TF, Empting M Hit-to-lead optimization of a latency-associated nuclear antigen inhibitor against Kaposi's Sarcoma-associated herpesvirus infections. *Eur. J. Med. Chem.* 202; 112525
12. Koch S, Damas M, Freise A, Hage E, Dhingra A, Rückert J, Gallo A, Tegge W, Brönstrup M, Brune W, Schulz TF Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression. *PLoS Pathogens* 2019; 15(5):e1007743
13. Abere B, Samarina N, Gramolelli S, Rückert J, Gerold G, Pich A, Schulz TF Kaposi's sarcoma-associated Herpesvirus nonstructural membrane protein pK15 recruits the class II phosphatidylinositol 3-kinase PI3K-C2 $\alpha$  to activate productive viral replication. *J. Virol.* 2018; 92:e00544-18. <https://doi.org/10.1128/JVI.00544-18>
14. Abere B, Mamo TM, Hartmann S, Samarina N, Hage E, Rückert J, Hotop SK, Büsche G, Schulz TF The Kaposi's Sarcoma-associated Herpesvirus (KSHV) non-structural membrane protein K15 is required for viral lytic replication and may represent a therapeutic target. *PLoS Pathog.* 2017; 3(9): e1006639. doi: 10.1371/journal.ppat.1006639
15. Marigiò G, Koch S, Zhang G, Weidner-Glunde M, Rückert J, Kati S, Santag S, Schulz TF Kaposi Sarcoma Herpesvirus Latent Nuclear Antigen (LANA) recruits components of the MRN (Mre11-Rad50-Nbs1) complex to modulate an innate immune signaling pathway and viral latency. *PLoS Pathog.* 2017; 13:e1006335. doi: 10.1371/journal.ppat.1006335.
16. Zhang G, Chan B, Samarina N, Abere B, Weidner-Glunde M, Buch A, Pich A, Brinkmann MB, Schulz TF. Cytoplasmic isoforms of Kaposi Sarcoma Herpesvirus LANA recruit and antagonize the innate immune sensor cGAS. *Proc Natl Acad Sci U S A.* 2016; 113(8):E1034-43. doi: 10.1073/pnas.1516812113.
17. Gramolelli S, Weidner-Glunde M, Abere B, Viejo-Borbolla A, Bala K, Rückert J, Kremmer E, Schulz TF. Inhibiting the recruitment of PLC $\gamma$ 1 to Kaposi's Sarcoma Herpesvirus K15 protein reduces the invasiveness and angiogenesis of infected endothelial cells. *PLoS Pathog.* 2015; 11(8):e1005105. doi: 10.1371/journal.ppat.1005105

18. **Hellert J, Weidner-Glunde M, Krausze J, Lünsdorf H, Ritter C, Schulz TF\*, Lührs T\***. (2015) The 3D-structure of Kaposi's sarcoma herpesvirus LANA c-terminal domain bound to DNA. *Proc Natl Acad Sci U S A*. 2015; 112: 6694-9. \*joint senior author
19. **Bala K, Bosco R, Gramolelli S, Haas DA, Kati S, Pietrek M, Hävemeier A, Yakushko Y, Singh VV, Dittrich-Breiholz O, Kracht M, Schulz TF** Kaposi's Sarcoma Herpesvirus K15 protein contributes to virus-induced angiogenesis by recruiting PLC $\gamma$ 1 and activating NFAT1-dependent RCAN1 expression. *PLoS Pathogens* 2012; 8:e1002927. doi: 10.1371
20. **Glenn, M., Rainbow, L., Aurade, F., Davsion, A., Schulz, T.F.** Identification of a multiply spliced gene of KSHV/HHV8 with similarities to the latent membrane proteins of EBV. *J. Virol.* 1999; 73: 6953 – 6963
21. **Rainbow, L., Platt, G.M., Simpson, G.R., Sarid, R., Gao, S.-J., Stoiber, H., Herringston, C.S., Moore, P.S., Schulz, T.F.** The 222-234 kd nuclear protein (LNA) of Kaposi's sarcoma - associated herpesvirus (KSHV/HHV 8) is encoded by orf73 and a component of the latency-associated nuclear antigen (LANA). *J. Virol.* 1997; 71: 5915-5921
22. **Simpson GR, Schulz TF\*, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard M, Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A, Tedder RS, Weller IVD, Weiss RA, Moore PS** Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. *Lancet* 1996; 348:1133 – 1138 \*corresponding author
23. **Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FEA, Aldam DM, Denton AS, Miller RF, Weller IVD, Weiss RA, Tedder RS, Schulz TF** Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma *Lancet* 1995; 346:799-802.